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Whipple's disease was describedin 1907 and was designated"intestinallipodystrophy,"despite the detection of bacteriain
1 specimen. This finding was later substantiatedby the success of antibiotic therapy,which resulted in dramaticclinical
responses, and by use of electron microscopy,which detected monomorphic bacilli in affected tissues. Many attempts at
culture failed, and these bacteriawere characterizedas actinomycetesfor the first time by means of broad-range16S rDNA
amplification and molecular phylogenetic methods. The name "Tropherymawhippelii"was proposed for this bacterium.
Whipple's disease is a systemic disease that affects many organ systems, producing protean manifestations.This article
summarizesrecent developmentswith regardto this topic as well as unansweredquestions regardingthe pathogenesisand
acquisition of infection, the biology and ecology of the organism,the clinical spectrumof disease, diagnosis of the disease,
and therapy.
In 1907, George H. Whipple described autopsy findings for a
36-year-old patient who had a 5-year history of an illness that
was dominated by arthritis, fever, chronic cough, weight loss,
and diarrhea [1]. He observed deposits of fat and fatty acids
in the intestinal mucosa and mesenteric lymph nodes; he assigned the term "intestinal lipodystrophy" to this disease. In
1961, bacteria were detected in affected tissues by means of
electron microscopy [2, 3]. However, subsequent attempts to
cultivate these bacteria failed. In the early 1990s, characterization on the basis of molecular phylogeny was achieved by
means of broad-range bacterial rDNA PCR analysis [4, 5]. A
newly acquired 16S rDNA sequence revealed a phylogenetic
relationship between the bacterium and the actinomycetes, although there was no known close relative, and the name Tropheryma whippelii was proposed [5]. Whipple's disease is considered to be rare. In the only published monograph on this

entity, Dobbins [6] compiled information from 696 cases available through 1986.

CLINICAL MANIFESTATIONS
Whipple's disease is a systemic disease with a propensity for
affecting the gastrointestinal tract [6]. Its clinical manifestations
have been compiled and extensively discussed in several case
series and reviews [6-11]. Intestinal manifestations are most

commonly reported; these help to define what is known as
"classical" Whipple's disease, which includes weight loss, diarrhea, and abdominal pain. Intestinal symptoms are often preceded by arthralgiasfor several years (up to 30 years). Abdominal and peripheral lymphadenopathies are also common.
Extraintestinaldisease often involves the brain and the heart.
Endocarditis, myocarditis, and pericarditis have all been reported.
Symptomatic Whipple's disease of the CNS can occur
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patientswho do not havegrosslyapparentintestinaldisease[6,
15]. "Exotic,"or rare,manifestationsof Whipple'sdiseaseincludeprostheticjoint infection[16], spondylodiskitis[17], and
extremeinsomnia [18].
DIAGNOSIS

fever,and minorgastrointestinal
complaints[6]. In thesecases,
upper gastrointestinalendoscopyis indicated,and severalbiopsy specimensfrom the lowerduodenumshouldbe obtained
(becausepatchydiseaseinvolvementis possible)and subjected
to histopathologicexamination.In his monograph,Dobbins
[6] provideda list of additionalclinicalsettingsin whichWhipple's diseaseshould be suspected.Dementiawith no apparent
cause, or chest pain and chronic cough with lung infiltrates
that simulatesarcoidosisare examplesof syndromeson this
list. Enlargedintra-abdominal
andperipherallymphnodesthat
arehypodenseon CTscansandhypoechoicon ultrasonograms,
as well as skin hyperpigmentation
that is not relatedto adrenal
dysfunction or hyperbilirubinemia,may provide diagnostic
hints [6]. In casesof suspectedextraintestinal
Whipple'sdisease,
it is advisableto obtainspecimensfrom the affectedanatomic
sites, in additionto intestinalbiopsy specimens.This strategy
appliesto initial presentationswith minimal or no apparent
intestinalinvolvement[15, 27]; in addition,it appliesto patients aftertreatmentof Whipple'sdisease,when eitherclinical
findingspersist or new atypicalpresentationsoccur, as is illustratedby a case of extremeinsomniaoccurring8 yearsafter
diagnosisand treatmentof intestinaldisease [18].

Histopathologicor cytologicalanalysisby means of periodic
acid-Schiff(PAS)stainingare the standardmethodsused for
featureof the
diagnosisof Whipple'sdisease.The characteristic
disease is the presenceof macrophageswith intracellularinclusionsthat reactwith the PASstainand appearmagenta(i.e.,
sickleformparticle-containingcells), especiallyin the lamina
propriaof the small intestine.The inclusionsreflectaccumulations of degradedcell wall and intactbacteria.Electronmicroscopyhas been recommendedto confirm histopathologic
diagnoses,especiallyin extraintestinalsites [6].
DiagnosticPCRassaysfor T whippeliiareincreasinglybeing
usedto establishandconfirmthe diagnosisof Whipple'sdisease
[19-24]. Although data on clinical sensitivityand specificity
are scarceand difficultto acquire,well-optimizedPCRassays
are capableof detectingas few as 10 copies of the 16S rRNA
gene per reaction,and PCR analysisof histologicallypositive
specimensalmostalwaysyieldspositiveresults[19, 20]. There THERAPY AND MONITORING
is stillroom for improvementof PCRtestingandimprovement
in the selection of optimal specimentypes. For example,not
Thereare still no randomized,double-blindtrialsof different
all PCRassayshavebeen validatedwith thoroughmeasurement antibioticregimensupon which to base recommendationsfor
of performancecharacteristics
and identificationof amplified the treatmentof Whipple'sdisease.On the basis of the comAn
overview
of
products.
diagnosticmethodsis given in table bined observationsfrom manycasereports[6], severalpatient
1.
series [9-11], and retrospectiveanalyses[30, 31], the therapy
most commonly associatedwith clinical success is initial iv
Despitethe apparentrarityof Whipple'sdisease,the factthat
it can occur in the absenceof "classical"intestinalmanifesta- treatmentwith penicillinG and streptomycin,or a third-gentions emphasizesthe importanceof consideringthe diagnosis eration cephalosporin,followed by administrationof co-triin patientswith atypicalpresentations.Certainly,Whipple'sdismoxazolefor at least 1 year (table 2). The main objectivesof
ease shouldbe suspectedin patientswith weightloss, diarrhea, treatmentof Whipple'sdiseaseareto eradicateprimary(usually
arthralgias,and abdominalpain or in patientswith arthralgias, intestinal)diseaseand to preventrelapse.Consideringthe troTable 1.

Diagnostic methods for Whipple's disease.

Method

Comments

Sample types

Routinehistologicanalysis
(with PASstaining)

Tissues (e.g., intestinal,brain,etc.)

Cytologicalanalysis (with
PASstaining)
Electronmicroscopy

Body fluids (e.g.,
CSF;jointfluid,
vitreousfluid)
Tissues, body fluids

PCRanalysis

Tissues, body fluids

Standardmethod; PAS-positive,diastase-resistant,
non-acid-fastinclusionsin macrophagesare highly
suggestive
Body fluids should be fresh (s1 h)

Recommendedfor confirmationof routinehistopathologic
analysis;time consuming;shows bacteriaof typicalsize
and shape
Alternativetest for confirmation;availablein researchand reference laboratoriesand few commerciallaboratories

NOTE. PAS,periodicacid-Schiff.
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Reference
[6, 25]

[6, 15, 26, 27]

[6, 28, 29]

[5, 19-24]

Table2.

Recommended
therapyfor Whipple'sdisease.

Timing
Initially(first10-14 days)
Longterm (-1 year)

Firstchoice

Alternative

Pen G (6-24 millionU iv q.d.) plus Stm (1 g im q.d.) or
third-generation
cephalosporin(e.g., Ctri2 g iv q.d.)
TMP-SMZ(160 mg/800 mg po b.i.d.)

TMP-SMZ(160 mg/800 mg po b.i.d.)
Dox (100 mg po b.i.d, Cfix(400 mg
po b.i.d.),or Pen V potassium
(500 mg po q.i.d.)

NOTE. Dox, doxycycline;Cfix,cefixime;Ctri,ceftriaxone;Pen, penicillin;Stm, streptomycin;TMP-SMZ,
trimethoprim-sulfamethoxazole.

pism of T whippeliifor the CNS and, thus, the threatposed
by relapsesin the CNS [26, 30], earlyuse of drugswith good
penetrationof the blood-brainbarrieris important.
Well-established
protocolsfor patientfollow-upduringand
after therapyare also lacking.Routineperiodicassessmentof
sites of frequentdiseaseinvolvement,such as the abdominal
lymph nodes, cardiovascular
system,and CNS,would be prudent. PAS-positive macrophages undergo morphological
changesbut persistfor up to severalyears[25];intactbacterial
cells (withstatusdeterminedby meansof electronmicroscopy)
areshorterlived,disappearingaftera few months [28]. Positive
resultsof PCRanalysisof intestinalspecimens(resultsindicate
bacterialDNA) convertto negativeresultsusuallywithin 1-12
months afterinitiationof therapy[19].
One study suggestedthat PCR analysisof intestinalspecimens maybe usefulfor monitoringthe efficacyof therapy[20],
whereasanother investigationfound that some patients for
whom the results of PCR analysisof intestinalsamples are
negativedeveloprelapsesin the CNS [19]. Cytologicalor PCRbased examinationsof CSF may be useful for both initial
assessmentand monitoringof the developmentof CNS complicationsduringtherapy[26]. At present,there are no solid
datathat one can use to decidewhen antibiotictherapyshould
be terminated,but therapywith an overalldurationof at least
1 year is considerednecessary[30, 31]. The currentlyavailable
data, albeit scant, suggestthat posttreatmentprogressionand
relapseof diseaseare causedby the originalinfectingbacterial
strain(seebelow),ratherthanby reinfectionby a differentstrain.
IS WHIPPLE'S DISEASE UNDERDIAGNOSED?
The question of whethera diseaseor infectionhas been underdiagnosednaturallyariseswhen new, more-sensitivediagnostic methods become available.Whipple'sdiseasehas traditionallybeen recognizedby its "classical"clinical features.
One would expectthatthis circumstanceimposesa biason the
recognitionand descriptionof the full spectrumof disease
manifestations.For example,Whipple'sdiseasewas retrospectively diagnosedin a specimenfrom 1895 that was stored at
the WestminsterMuseum in London,by means of the newly
availablePASstain [32]. The introductionof endoscopyin the

1970s,used in combinationwith PASstaining(whichwas introducedin the 1940s),led to the diagnosisof caseswith intestinal pathologybut "atypical"symptoms.By use of other
diagnosticprocedures(e.g., radiographically
guidedtissue bior
PCR
cases
of
extraintestinal
diseaseaccomopsy
analysis),
paniedby minimalor no apparentintestinalinvolvementhave
been diagnosed[15, 17, 27, 33]. These diagnosedcasesmight
have been missedbeforethe availabilityof these methods.
At the same time, Whipple'sdiseaseis consideredto be invariablyfatal when it is not treatedwith antibiotics[6]. If a
significantnumberof caseswere unrecognizedand untreated,
one might expect some of them to be discoveredat autopsy;
however,this is not a common event.It is possiblethat spontaneous remissionor resolution of disease occurs, and it is
conceivablethat patientswith unsuspecteddiseaseare cured
whentheyundergoshortcoursesof antibiotictherapyforother
complaints.In this context,the observationby Fleminget al.
[9] of a case of long-termremissionafter a 5-day course of
antibiotictherapyis intriguing.Furthermore,it has been suspected that the frequentuse of antibioticsin generalmedical
practice,in dosages and durationsinadequatefor cure, may
have alteredthe age of presentationwith Whipple'sdisease
duringthe past severaldecades[34].
Overall,it seems unlikelythat a significantnumberof advancedcasesof Whipple'sdiseasego undiagnosed;however,it
remainsunclearwhetherthis theoryholds true for less severe
cases and for those that may be cured by short courses of
antibiotics.Over a period of 30 years, Dobbins [6] noted a
relativelystableincidenceof Whipple'sdisease,with a ratioof
1 publishedcaseto every4 unpublishedcases.Givenhow little
we know about the naturalhabitatof the organism(see the
Pathogenesisand Acquisitionof Infection section) and the
route(s) of transmissionto humans, it is even more unclear
whether asymptomatic,transient,or persistentinfectionsin
privilegedanatomiccompartments(those that are usuallyfree
of microorganisms)are common occurrences.
MICROBIOLOGY
Electronmicroscopyof tissue specimensfrom patientswith
Whipple's disease reveals uniformityin bacterialsize (0.2-
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0.25 X 1-2.5 ,tm) and shape [6, 29]. The bacteria are surrounded by an unusual outer membrane not found in other
gram-positive bacteria and unlike those seen in gram-negative
bacteria: it appears to lack lipopolysaccharide. Some investigators have concluded that this membrane may be of host
origin [29]. Phylogenetic analysis based on 16S rDNA sequence
amplification with broad-range bacterial PCR primers revealed,
for the first time, that the bacterium is a member of the actinomycetes [4, 5]; a subsequent analysis performed 4 years
later, in which an expanded 16S rRNA sequence database was
used, placed the organism between the genus Cellulomonasand
a rare group of actinomycetes with group B peptidoglycan [35],
with relatively distant relationships (16S rRNA similarity,
91%-92%) to members in either group. As a result, the lack
of a known close relative prevents meaningful inferences of
physiology and function for T whippelii from well-studied cultivated members of this bacterial division.
Attempts to cultivate the Whipple's disease bacterium have
had a troubled history; many attempts have been undertaken,
and the "successful" isolation of a causative agent in a number
of reports turned out to be nonreproducible [6]. One notable
report by Schoedon et al. [36] was published in 1997. Heart
valve tissue specimens obtained from 2 infected patients were
inoculated onto human macrophages that had been treatedwith
IL-4 in cell culture. This treatment impairs the microbicidal
killing mechanisms of macrophages and facilitates the growth
of intracellular microorganisms. Accumulation of PAS-positive
intracellular inclusions and the persistence of PCR-amplified
product after cell passage were interpreted as being indicative
of growth of T whippelii. However, these results have not been
reproduced by other researchers (Maiwald and Relman, unpublished data; [37]). A nonvalidated PCR assay was used by
Schoedon et al. [36], and the PAS reagent stains bacterial cell
wall components even in advanced stages of degradation [6, 25].
Raoult et al. [38] reported another promising set of findings.
An aortic valve tissue sample from a patient with endocarditis
was inoculated onto a human fibroblast cell line, without special
pretreatment of the cells (e.g., deactivation by cytokines). After
65 days of incubation, a cytopathic effect was observed, and
microorganisms were seen by means of several staining procedures, including PAS staining. Fibroblast culture materialwas
passaged 7 times, and after 285 days, a 3750-cm2 infected cell
monolayer was obtained from an initial inoculum of 1 cm2 of
cells. Several stains showed bacteria, and results of PCR analysis
were positive for T. whippelii after each passage. The doubling
time of the bacteria was estimated to be 18 days under these

inal heart valve. Serological tests were also performed using
cultured material as antigen. Elevated titers of IgM antibody
were detected in 7 of 9 serum samples from different patients
with Whipple's disease and in 3 of 40 serum samples from
controls, whereas titers of IgG antibody were elevated for all 9
patients with Whipple's disease and for 29 of 40 controls.
Taken together, there is good evidence that these investigators
have propagated T. whippelii ex vivo. However, the story is not
yet complete: there is no documentation, by use of a quantitative method (e.g., quantitative PCR analysis), of an increase
in bacterial numbers; this propagated organism did not originate from a patient with typical or "classical"Whipple's disease; and nothing is currently known about whether the described culture conditions reflect the optimal growth conditions
for this organism. Although the reported doubling time renders
this culture method impractical for routine laboratories, this
report may constitute an important step toward the ultimate
goal of routine propagation of T whippelii in the laboratory.
Basic epidemiological tasks, such as tracking routes of infection and determining linkage between cases, requirebacterial
strain identification and discrimination. The first step toward
strain typing of T whippelii has been achieved using the bacterial 16S-23S rRNA intergenic spacer sequence. This sequence
was initially determined from a specimen from 1 patient with
Whipple's disease [35]; variability of the spacer sequence was
addressed in subsequent studies [39-41]. One study [39] found
homogeneity in the spacer sequences in 9 Swiss individuals;
another study by the same group of investigators [40] found
3 different spacer types in 28 individuals whose geographic
locations were not specified. A third study [41] found 5 different spacer types in 56 specimens from 43 patients from 4
countries; this study described the most common types, "1"
and "2," in a similar ratio (~1:2) in patients from the United
States, Germany, and Switzerland. Specimens from different
anatomic sites generally yielded the same spacer types in individual patients, which supports the concept of systemic dissemination of a single bacterial clone [41]. However, 1 intestinal
biopsy sample from 1 patient contained 2 sequence types, which
raised, for the first time, the possibility of double infection with
T. whippelii [41]. Despite these efforts, the 16S-23S rRNA intergenic spacer sequence with its 6 known variant types may
not be adequate for discrimination between T whippeliistrains
at a clinically relevant level. A more variable genetic locus or
set of loci needs to be identified for this purpose.

PATHOGENESIS AND ACQUISITION OF
INFECTION

particular growth conditions, which is slower than that of Mycobacterium leprae in a mouse model (12 days). Immunofluorescence staining that used samples of the patient's serum as

Important unresolved issues pertaining to the pathogenesis of

well as murine polyclonalantibodiesraised againstcultured
materialrevealedbacteriain and on fibroblastsand in the orig-

Whipple'sdiseaseincludethe sourceand routeof infectionand
the possibilityof differentialhost susceptibility.Verylittle is
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presently known regarding these issues. Because of the prominence of intestinal manifestations, an oral route of acquisition
is assumed [6]. The highest concentration of visible bacilli is
usually found within the lamina propria of the small intestine,
subjacent to the epithelial basement membrane [28]. It seems
likely that bacilli translocate across or between the epithelial
cells from the luminal to the basal zone, cross the basement
membrane, and then elicit a macrophage-predominant response. Despite the recent report describing the propagation
of T whippelii in vitro with use of eukaryotic cells [38], intact
and dividing bacteria are most often found in vivo outside of
host cells [29]. Thus, this microbe may actually be an extracellular pathogen, and the keys to its optimal cultivation may
be found within the microenvironment of the lamina propria.
Transient (during active disease) as well as persistent (after
therapy) abnormalities of immune function have been described in patients with Whipple's disease [6, 42]; the persistent
abnormalities are presumed to serve as predisposing factors.
However, precise immune defects have not been adequately
defined. The notion of preexisting host impairment is supported by the observation of opportunistic infections in some
patients with Whipple's disease [43]. One patient appears to
have benefited from adjuvant IFN--ytreatment [44]. T.whippelii
DNA has also been detected in a patient with AIDS [45]. However, the issue is complicated by the common occurrence of
malabsorption and malnutrition in patients with AIDS and
their consequences for immune cell function. Further reports
on the detection of T whippelii in patients with AIDS have not
appeared, but detection of this bacterium may have been missed
by routine diagnostic examinations. Taken together, if there is
a host genetic defect, the phenotype is relatively subtle.
Two recent publications reported PCR-based detection of T.
whippelii DNA in specimens from persons with no signs of
Whipple's disease. In one series, results of tests of saliva samples
from 14 (35%) of 40 apparently healthy persons were positive
[46] for T. whippelii; in another series, results of PCR analysis
of intestinal biopsy or gastric juice samples were positive for
14 (13%) of 105 patients undergoing endoscopy for reasons
other than suspected Whipple's disease [47]. These investigators
speculated that T whippelii is a commensal of the normal human gastrointestinal tract. On the other hand, severalpublished
series found no evidence for T whippelii DNA in control intestinal biopsy specimens by use of PCR analysis [19-22]. Although additional data on T. whippelii DNA in saliva are not
available, combined results from several institutions would argue against the human small intestine being a significant reservoir for T whippelii [48].
In the analysis by Dobbins [6], farmers and carpenters were
the professional groups most commonly affected by Whipple's

disease.An epidemiologicalstudy in Germany[34] found a
relativelyhomogeneousgeographicand temporaldistribution

of cases. Most of the known phylogenetic relatives of T whippelii, especially those on closer branches of the evolutionary
"tree," are environmental organisms or plant pathogens [35].
These features point to a potential environmental habitat for
T whippelii and to the source of infection. Indeed, the results
of a PCR-based search in 5 different sewage treatment plants,
representing rich polymicrobial communities outside the human host, revealed that 25 of 38 samples were positive for T

whippelii[49].

CONCLUSIONS AND PERSPECTIVES
The Whipple's disease bacterium-recalcitrant to cultivation,
encased by a thick and unique cell wall, and without known
close relatives-has been slow to reveal its secrets. However,
the past 10 years have been marked by a number of important
findings. The organism has been identified and characterized
at a molecular level, and a reliable diagnostic signature has been
defined [4, 5]. The first stages of a bacterial typing scheme have
been established [35, 40, 41]. A recent report suggests that
propagation of the bacterium in vitro may be possible [38].
From either a propagated organism in ex vivo culture or by
use of broad-range amplification methods with clinical specimens, we are certain to acquire a great deal of additional genotypic and phenotypic information about this bacterium during
the next 5 years, leading to tools for serological diagnosis, development of new therapeutics, and insights into disease
pathogenesis.
Genomics and a rapidly accumulating set of associated techniques are likely to yield a more complete genomewide perspective on the capabilities, gene responses, and deficiencies of
this bacillus. As has been the case with other actinomycetes,
we can expect to find unusual metabolic pathways,biosynthetic
products of relevance to virulence (and of possible use as novel
drugs), and clues about its natural environment. Sensitive and
specific detection methods that are currently available can and
will be used to define the preferred habitats of T whippelii
within and outside of the human host. For example, fluorescent
in situ hybridization techniques can be used to map the anatomic distribution of T whippelii rRNA in affected tissues. As
observed with Legionellapneumophila, initial laboratorygrowth
conditions (charcoal-yeast extract agar) may prove to be quite
distinct from those that the organism has selected in the natural
world (within free-living amoebae). Finally, a wide variety of
tools and data sets will permit a reassessment of host susceptibility to Whipple's disease.
The Human Genome Project, by facilitating comprehensive

surveys of host gene polymorphismsand variant gene responses,will providesignificantcontributionsto the study of
infectiousdisorderssuch as Whipple'sdisease,for which relevant laboratorymodels of diseaseare unavailable.It is a safe
EMERGINGINFECTIONS* CID 2001:32 (1 February) ? 461

bet that, during the next 10 years, many of the remaining
mysteries about this disease and disease agent will be explained,
and, with these explanations, profoundly important biological
principles will be established

22.

23.
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